Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Is semaglutide safe during pregnancy?
Semaglutide is contraindicated during pregnancy. The FDA label cites adverse fetal outcomes in animal studies; all phase 3 programmes excluded pregnant women.
What happens after you stop retatrutide?
Retatrutide has no withdrawal trial yet, so here is what the semaglutide and tirzepatide discontinuation data suggest about stopping.
MOTS-c and BPC-157: the evidence so far
MOTS-c and BPC-157 are unapproved peptides with mostly animal evidence. Here is what the research shows and what an FDA panel just voted on.
Peptide healing stacks after surgery
Peptide healing blends combine BPC-157, TB-500 and GHK-Cu. Here is what the evidence does and does not support for recovery after surgery.
Combining GLP-1 drugs and tesamorelin
No trial has tested combining retatrutide, tirzepatide and tesamorelin, and here is why doing so without clinical supervision is a real risk.
Do genes change how tirzepatide works?
A 2026 endocrinology review asks whether GLP-1 and GIP receptor gene variants help explain why people respond differently to tirzepatide and semaglutide.
FDA panel backs compounded BPC-157, KPV
An FDA advisory panel voted 8 to 6 to recommend that compounding pharmacies be allowed to prepare BPC-157 and KPV, two unapproved peptides.
FDA panel backs BPC-157 compounding
The FDA's PCAC voted narrowly on 23 July 2026 to recommend allowing compounding pharmacies to produce BPC-157, KPV, TB-500, and MOTS-c. The vote is non-binding.
GLP-1 telehealth oversight and rare disease
A STAT investigation alleged LifeMD reviewed GLP-1 prescriptions at 25 cases per hour, raising safety questions for a drug class with a boxed warning.
Retatrutide: Lilly plans FDA filing in 2027
New TRIUMPH data give Lilly the evidence to file an FDA application for retatrutide in Q1 2027. The cardiovascular outcomes question remains open.
Semaglutide for postpartum prediabetes
A Belgian trial is testing whether once-weekly semaglutide can stop postpartum prediabetes after gestational diabetes from becoming type 2 diabetes.
Semaglutide proteomics: 16 studies reviewed
A 2026 review of 16 proteomics studies maps what semaglutide does to proteins across human and animal tissues, from fat metabolism to cardiac remodelling.